[Neuroactivating mechanism of action of the new trophinotropic drug cerebral].
The new drug cerebral, as well as its low-molecular-weight (LMW) fraction (MW, < or = 500 Da) separated from a ready-to-use commercial form of this new neutrotropic drug, increases the level of synthesis and secretion of the nerve growth factor (NGF) in rats under conditions of experimental hemorrhagic stroke (HS), while not influencing the NGF synthesis and secretion in intact animals. This neuroactivating effect of the trophinotropic drug cerebral and its LMW fraction in the acute HS development stage was observed upon intranasal administration. In comparison with parenteral (intraperitoneal) administration, the intranasal introduction provides for the optimum drug delivery to the CNS bypassing the blood-brain barrier. Trophinotropic agents are a new class of drugs with neuroactivating mechanism of action upon the NGF synthesis and secretion under HS conditions.
Makarenko
A N
AN
Vasil'eva
I G
IG
D000281:Administration, Intranasal; D000818:Animals; D001921:Brain / Q000187:drug effects*; D002543:Cerebral Hemorrhage / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D015870:Gene Expression / Q000187:drug effects; D008297:Male; D008970:Molecular Weight; D009414:Nerve Growth Factors / Q000235:genetics / Q000378:metabolism*; D018696:Neuroprotective Agents / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D015854:Up-Regulation
D009414:Nerve Growth Factors; D018696:Neuroprotective Agents